Fibroblast growth factor (FGF) family ligands

CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) , with IC 50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectivelyIn VitroCPL304110 (0-0.6 μM) dose-dependently inhibits

CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) , with IC 50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectivelyIn VitroCPL304110 (0-0.6 μM) dose-dependently inhibits

CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) , with IC 50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectivelyIn VitroCPL304110 (0-0.6 μM) dose-dependently inhibits

CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) , with IC 50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectivelyIn VitroCPL304110 (0-0.6 μM) dose-dependently inhibits

Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor exhibits potent activity against FGFR1-3 chondrocytes with IC 50 s of 4.5, 1.8, and 4.5 nM,

Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor exhibits potent activity against FGFR1-3 chondrocytes with IC 50 s of 4.5, 1.8, and 4.5 nM,

E7090 succinate is an orally available, selective and potent inhibitor of FGFR1 , FGFR2 and FGFR3 tyrosine kinase activities, with IC 50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.In VitroE7090 also inhibited the

E7090 succinate is an orally available, selective and potent inhibitor of FGFR1 , FGFR2 and FGFR3 tyrosine kinase activities, with IC 50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.In VitroE7090 also inhibited the

E7090 succinate is an orally available, selective and potent inhibitor of FGFR1 , FGFR2 and FGFR3 tyrosine kinase activities, with IC 50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.In VitroE7090 also inhibited the

Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of

FGF-1

FGF-1